ASX Release

12 November 2025

AROVELLA APPOINTS FORMER CSL CSO DR ANDREW NASH AS NON-EXECUTIVE DIRECTOR

MELBOURNE, AUSTRALIA 12 November 2025: Arovella Therapeutics Ltd (ASX: ALA) is pleased to announce the appointment of Dr Andrew Nash as Non-Executive Director, effective 12 November 2025.

Dr Nash has over 35 years of practical drug development experience and executive leadership in the biotech and pharmaceutical sector, most recently with Australia's largest and most successful pharmaceutical company, CSL. Dr Nash initially trained as an academic scientist after completing his PhD in Immunology. He then joined Zenyth (formerly Amrad Corp), where he advanced to become Chief Scientific Officer (CSO), and ultimately CEO before it was sold to CSL in 2006. Dr Nash was appointed CSO of CSL in 2020 and remained in that position until his retirement in March 2025.

Dr Nash has had a distinguished career, being elected as a Fellow of the Academy of Technological Sciences and Engineering in 2021, and as a Fellow of the Australian Academy of Science in 2025. He was the inaugural Chair of Jumar Bioincubator and is currently a Board Director at the Burnet Institute, the Garvan Institute of Medical Research, Brandon BioCatalyst and Denteric, a vaccine-focused biotechnology company in Melbourne.

Arovella's CEO and MD, Dr Michael Baker, remarked: "I have had the pleasure of getting to know Andrew since we established Arovella's first office in the Jumar Bioincubator in 2023. We are delighted that someone with Andrew's track record, with relevant experience at a senior level across all facets of drug development and commercialisation, has agreed to join Arovella's Board of Directors as the Company transitions to a clinical-stage company with a promising pipeline."

Dr Andrew Nash commented: "I am delighted to join Arovella's Board of Directors. I see great potential in Arovella's approach to tackling blood cancers and solid tumours. I have had the pleasure of meeting several of the team members, who are equally impressive as the technology being developed. This is clearly an exciting time for the company, as it looks to take its first product into clinical trials. In addition, the pipeline is developing well, and the balance sheet is strong. I look forward to adding value on multiple fronts."

The intention is for Dr Nash to transition from the role of Non-executive Director to Non-executive Chairman of the Board, and the Company looks forward to providing an update in due course.

Release authorised by the Arovella Limited Board of Directors.

Dr Michael Baker
Chief Executive Officer & Managing Director
Arovella Therapeutics Ltd
Tel +61 (0) 403 468 187
investor@arovella.com

NOTES TO EDITORS:

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Arovella will also incorporate its IL-12-TM technology into its solid tumour programs.

Glossary: iNKT cell – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1, which is expressed on some immune cells and cancer cells; **αGalCer** – alpha-galactosylceramide is a specific ligand for human and mouse natural killer T cells. It is a synthetic glycolipid.

For more information, visit www.arovella.com

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding the actions of third parties and financial terms. These factors and assumptions are based upon currently available information, and the forward-looking statements herein speak only of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; the risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.